{"status": "ok", "totalResults": 625, "articles": [{"source": {"id": "techcrunch", "name": "TechCrunch"}, "author": "Kate Clark", "title": "Indigo raises $250M, launches marketplace to help farmers get paid for quality grain", "description": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026", "url": "http://techcrunch.com/2018/09/18/indigo-raises-250m-launches-marketplace-to-help-farmers-get-paid-for-quality-grain/", "urlToImage": "https://techcrunch.com/wp-content/uploads/2018/09/Indigo_Wheat1.jpeg?w=600", "publishedAt": "2018-09-18T13:00:15Z", "content": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026 [+2449 chars]"}, {"source": {"id": "business-insider", "name": "Business Insider"}, "author": "Lydia Ramsey and Charlotte Hu", "title": "The Trump administration's top health official isn't counting on pharma to bring down drug prices", "description": "Health and Human Services Secretary Alex Azar isn't counting on pharmaceutical companies to do the right thing when it comes to drug prices. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharma Pricing Summit on \u2026", "url": "https://www.businessinsider.com/hhs-secretary-alex-azar-on-drug-pricing-2018-9", "urlToImage": "https://amp.businessinsider.com/images/5a1ee1183dbef484008b8f22-2732-1366.jpg", "publishedAt": "2018-09-13T14:34:06Z", "content": "Department of Health and Human Services Secretary Alex Azar isn't banking on the pharmaceutical industry to fix the rising cost of prescription drugs in the US. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharm\u2026 [+1364 chars]"}, {"source": {"id": "techcrunch", "name": "TechCrunch"}, "author": "John Biggs", "title": "Meet the startups in the latest Alchemist class", "description": "Alchemist is the Valley\u2019s premiere enterprise accelerator and every season they feature a group of promising startups. They are also trying something new this year: they\u2019re putting a reserve button next to each company, allowing angels to express their intere\u2026", "url": "http://techcrunch.com/2018/09/20/meet-the-startups-in-the-latest-alchemist-class/", "urlToImage": "https://techcrunch.com/wp-content/uploads/2018/09/image151.png?w=653", "publishedAt": "2018-09-20T17:30:10Z", "content": "Alchemist is the Valley\u2019s premiere enterprise accelerator and every season they feature a group of promising startups. They are also trying something new this year: they\u2019re putting a reserve button next to each company, allowing angels to express their intere\u2026 [+10659 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (George Budwell)", "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://www.fool.com/investing/2018/09/07/why-exact-sciences-corporation-stock-rocketed-high.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493775%2Frocketman.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences ( NASDAQ:EXAS ), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-\u2026 [+1929 chars]"}, {"source": {"id": null, "name": "Futurity.org"}, "author": "Mark Michaud-Rochester", "title": "Common painkiller doesn\u2019t ease chronic pain after injury", "description": "A common painkiller doesn't offer much relief for people who have suffered a traumatic nerve injury. But there is some good news.", "url": "https://www.futurity.org/chronic-pain-painkiller-nerve-injury-1873382-2/", "urlToImage": "https://www.futurity.org/wp/wp-content/uploads/2018/09/pills-on-yellow_1600.jpg", "publishedAt": "2018-09-25T16:20:17Z", "content": "A common painkiller isn\u2019t effective in controlling the chronic pain that sometimes develops following traumatic nerve injurybut shows promise in relieving pain that may linger after surgery, according to a new study. The FDA has approved pregabalin, which Pfi\u2026 [+4206 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://www.fool.com/investing/2018/09/06/3-top-big-pharma-stocks-to-buy-now.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493451%2Fpharmaceutical-research.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4543 chars]"}, {"source": {"id": null, "name": "Entrepreneur.com"}, "author": "Isa Watson", "title": "Not Your Parents' Career Development", "description": "In today's world, professional success doesn't mean what it used to.", "url": "https://www.entrepreneur.com/article/319624", "urlToImage": "https://assets.entrepreneur.com/content/3x2/2000/20180919182539-GettyImages-661789569.jpeg", "publishedAt": "2018-09-20T13:30:00Z", "content": "September 20, 2018 6 min read Opinions expressed by Entrepreneur contributors are their own. For my parents, a career meant one thing: progressing through the ranks at a single company, climbing a corporate ladder where growth could be measured through regula\u2026 [+5785 chars]"}, {"source": {"id": "the-economist", "name": "The Economist"}, "author": null, "title": "Business this week", "description": "The Trump administration intensified its trade war with China, threatening to impose tariffs on a further $200bn-worth of goods, including tuna, chemicals and handbags.", "url": "https://www.economist.com/the-world-this-week/2018/07/12/business-this-week", "urlToImage": "/assets/the-economist-logo.png", "publishedAt": "2018-09-20T14:46:47Z", "content": "The Trump administration intensified its trade war with China, threatening to impose tariffs on a further $200bn-worth of goods, including tuna, chemicals and handbags. This came a few days after America fired its first salvo, levying duties on $34bn-worth of\u2026 [+4466 chars]"}, {"source": {"id": "the-economist", "name": "The Economist"}, "author": null, "title": "Business this week", "description": "The  IMF warned that the tariffs on imports threatened by both President Donald Trump and his trading partners could lower the annual growth rate of the global economy by 0.5 percentage points by 2020. The fund left its forecasts for global economic growth in\u2026", "url": "https://www.economist.com/the-world-this-week/2018/07/19/business-this-week", "urlToImage": "https://cdn.static-economist.com/sites/default/files/images/print-edition/20180721_WWP004_0.jpg", "publishedAt": "2018-09-20T14:46:47Z", "content": "The IMF warned that the tariffs on imports threatened by both President Donald Trump and his trading partners could lower the annual growth rate of the global economy by 0.5 percentage points by 2020. The fund left its forecasts for global economic growth in \u2026 [+4282 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "Deepak Patel", "title": "Oxytocin production by private companies: Delhi HC defers ban to November 1", "description": "The three petitioners in this case are Mylan Laboratories, Neon Laboratories and All India Drug Action Network (AIDAN). Pfizer and Mylan are two leading producers of Oxytocin in India.", "url": "https://indianexpress.com/article/business/companies/oxytocin-production-by-private-companies-delhi-hc-defers-ban-to-november-1-5378812/", "urlToImage": "https://images.indianexpress.com/2018/08/hammer-main1111.jpg?w=759", "publishedAt": "2018-09-28T22:26:49Z", "content": "Written by Deepak Patel | New Delhi | Published: September 29, 2018 3:56:49 am The Centre had issued a notification to implement the ban from September 1. However, the Centre clarified that private companies would be free to manufacture Oxytocin in India for \u2026 [+1792 chars]"}, {"source": {"id": "bloomberg", "name": "Bloomberg"}, "author": null, "title": "Pfizer to Idle Plants in North Carolina With Hurricane Florence Approaching", "description": null, "url": "https://www.bloomberg.com/tosv2.html?vid=&uuid=ec67c3a0-b5ed-11e8-a686-d35d83610e7e&url=L25ld3MvYXJ0aWNsZXMvMjAxOC0wOS0xMS9wZml6ZXItdG8taWRsZS1wbGFudHMtaW4tbm9ydGgtY2Fyb2xpbmEtYXMtaHVycmljYW5lLWFwcHJvYWNoZXM=", "urlToImage": null, "publishedAt": "2018-09-11T17:07:37Z", "content": "Your usage has been flagged as a violation of our terms of service. For inquiries related to this message please contact support. For sales inquiries, please visit http://www.bloomberg.com/professional/request-demo If you believe this to be in error, please c\u2026 [+280 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/", "title": "A Look At Pfizer's Business And Outlook", "description": "Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, Anti-Infective, Alimentary &amp;Metabolism, Neuroscience, Immunology drugs, along with its Legacy Pharma, Consumer, Biosimilar &amp; Other segment. Legacy Pharma, Consumer, Biosimilar\u2026", "url": "https://www.forbes.com/sites/greatspeculations/2018/09/10/a-look-at-pfizers-business-and-outlook/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fblogs-images.forbes.com%2Fthumbnails%2Fblog_25%2Fpt_25_188249_o.jpg%3Ft%3D1536604325", "publishedAt": "2018-09-10T18:32:00Z", "content": "Share to facebook Share to twitter Share to linkedin The Pfizer company logo is photographed at Pfizer Inc. headquarters, in New York, Monday, Dec. 4, 2017. (AP Photo/Richard Drew) Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, An\u2026 [+9107 chars]"}, {"source": {"id": null, "name": "Marketwatch.com"}, "author": "Philip van Doorn", "title": "Deep Dive: These Dow Jones Industrial Average stocks have been left behind as the index hits a record", "description": "The benchmark finally tops the record it made in January.", "url": "https://www.marketwatch.com/story/these-dow-jones-industrial-average-stocks-have-been-left-behind-as-the-index-hits-a-record-2018-09-20", "urlToImage": "http://s.marketwatch.com/public/resources/MWimages/MW-GQ437_MCDP_2_ZG_20180920161117.jpg", "publishedAt": "2018-09-20T20:42:00Z", "content": "The Dow Jones Industrial Average DJIA, +0.95% rose to an intraday high Thursday, closing with a 1% gain. The S&amp;P 500 Index SPX, +0.78% was up 0.8% after setting another intraday record, following the latest round of good economic news. Bloomberg said its \u2026 [+2537 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (George Budwell)", "title": "Why Amarin Corporation Stock Is Exploding Higher Today", "description": "Amarin's prescription fish oil pill proves the naysayers wrong in a big way.", "url": "https://www.fool.com/investing/2018/09/24/why-amarin-corporation-stock-is-exploding-higher-t.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F495191%2Ffish-oil.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-24T11:33:00Z", "content": "What happened Shares of the Irish biopharma Amarin Corp. ( NASDAQ:AMRN ) gained as much as 311% in pre-market trading today. What caused this explosive move northward? Amarin reported this morning that the prescription fish oil pill Vascepa met its primary en\u2026 [+1693 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://finance.yahoo.com/news/why-exact-sciences-corporation-stock-100000965.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/cuXO7YplZxOVKts6hNDIHw--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/motleyfool.com/e4f07b38fce926e7eda0457056f7069a", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences (NASDAQ: EXAS), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-m\u2026 [+2147 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Is Bristol-Myers Squibb Company a Buy?", "description": "This big pharma stock has some baggage, but it also claims two fast-growing blockbusters.", "url": "https://www.fool.com/investing/2018/09/09/is-bristol-myers-squibb-company-a-buy.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493827%2Fpills-foming-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-09T10:31:00Z", "content": "Bristol-Myers Squibb ( NYSE:BMY ) stock has underperformed the S&amp;P 500 index so far this year. It's also trailed well behind most of its peers, but it could be worse. Earlier in 2018, Bristol-Myers Squibb (BMS) was down 17%; now the stock has climbed back\u2026 [+3494 chars]"}, {"source": {"id": null, "name": "Seekingalpha.com"}, "author": "First Genesis Consulting", "title": "Pfizer And Conatus: Emricasan And NASH", "description": "Pfizer has proven itself to be a pioneer of therapeutics for HIV infection, autoimmune, cardiovascular and gastrointestinal diseases as well as hematological an", "url": "https://seekingalpha.com/article/4207139-pfizer-conatus-emricasan-nash", "urlToImage": "https://static2.seekingalpha.com/images/marketing_images/numbers_words_signs/signs/analysis.jpeg", "publishedAt": "2018-09-19T13:44:12Z", "content": "Money won't create success, the freedom to make it will - Nelson Mandela Investment Thesis Pfizer Inc. ( PFE ), a large-cap ($251B) multi-billion global biopharmaceutical company, gained pharmaceutical celebrity status when sildenafil citrate marketed globall\u2026 [+17394 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know", "description": "Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.", "url": "https://finance.yahoo.com/news/pfizer-pfe-outpaces-stock-market-214509813.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/1MpaQeAGbKW4njUAW3XfGw--~B/aD00MjE7dz02MzU7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/zacks.com/1154d43aaeb65735a640003549116295", "publishedAt": "2018-09-14T21:45:09Z", "content": "In the latest trading session, Pfizer (PFE) closed at $42.97, marking a +0.34% move from the previous day. This change outpaced the S&amp;P 500's 0.03% gain on the day. At the same time, the Dow added 0.03%, and the tech-heavy Nasdaq lost 0.05%. Coming into t\u2026 [+2831 chars]"}, {"source": {"id": null, "name": "Sciencedaily.com"}, "author": null, "title": "Common painkiller not effective for chronic pain after traumatic nerve injury", "description": "A new study finds that pregabalin is not effective in controlling the chronic pain that sometimes develops following traumatic nerve injury. The results of the international study, which was driven by an effort to identify effective non-opioid pain medication\u2026", "url": "https://www.sciencedaily.com/releases/2018/09/180924144037.htm", "urlToImage": null, "publishedAt": "2018-09-24T18:40:37Z", "content": "A new study out today in the Journal of Neurology finds that pregabalin is not effective in controlling the chronic pain that sometimes develops following traumatic nerve injury. The results of the international study, which was driven by an effort to identif\u2026 [+3869 chars]"}, {"source": {"id": null, "name": "Seekingalpha.com"}, "author": "The Value Investor", "title": "Elanco Animal Health - Good For Animals, Good Investment?", "description": "Elanco Animal Health is the former animal health business from Eli Lilly. Following the successful spin-off of Zoetis from Pfizer, Lilly is pursuing the same st", "url": "https://seekingalpha.com/article/4207907-elanco-animal-health-good-animals-good-investment", "urlToImage": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "publishedAt": "2018-09-24T15:11:10Z", "content": "Elanco Animal Health ( ELAN ) has gone public in an offering which was well received by investors. The company has been around for a very long time already as it was founded in 1954 and ever since has been part of Eli Lilly ( LLY ). The goal of the spin-off i\u2026 [+6058 chars]"}]}